• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CNS Neurosci Ther . Shared genetics and causal association between plasma levels of SARS-CoV-2 entry receptor ACE2 and Alzheimer's disease

tetano

Editor, Senior Moderator
CNS Neurosci Ther


. 2024 Jul;30(7):e14873.
doi: 10.1111/cns.14873. Shared genetics and causal association between plasma levels of SARS-CoV-2 entry receptor ACE2 and Alzheimer's disease

Yan Zhang[SUP] 1 [/SUP], Fang Xu[SUP] 2 [/SUP], Tao Wang[SUP] 3 4 [/SUP], Zhifa Han[SUP] 5 [/SUP], Hong Shang[SUP] 6 [/SUP], Kevin Han[SUP] 7 [/SUP], Ping Zhu[SUP] 8 [/SUP], Shan Gao[SUP] 8 [/SUP], Xiaojie Wang[SUP] 9 [/SUP], Yanli Xue[SUP] 10 [/SUP], Chen Huang[SUP] 11 [/SUP], Yan Chen[SUP] 12 13 [/SUP], Guiyou Liu[SUP] 8 12 13 14 15 16 [/SUP]



Affiliations
Abstract

Background: Alzheimer's disease (AD) is the highest risk of COVID-19 infection, hospitalization, and mortality. However, it remains largely unclear about the link between AD and COVID-19 outcomes. ACE2 is an entry receptor for SARS-CoV-2. Circulating ACE2 is a novel biomarker of death and associated with COVID-19 outcomes.
Methods: Here, we explored the shared genetics and causal association between AD and plasma ACE2 levels using large-scale genome-wide association study, gene expression, expression quantitative trait loci, and high-throughput plasma proteomic profiling datasets.
Results: We found a significant causal effect of genetically increased circulating ACE2 on increased risk of AD. Cross-trait association analysis identified 19 shared genetic variants, and three variants rs3104412, rs2395166, and rs3135344 at chromosome 6p21.32 were associated with COVID-19 infection, hospitalization, and severity. We mapped 19 variants to 117 genes, which were significantly upregulated in lung, spleen, and small intestine, downregulated in brain tissues, and involved in immune system, immune disease, and infectious disease pathways. The plasma proteins corresponding to LST1, AGER, TNXB, and APOC1 were predominantly associated with COVID-19 infection, ventilation, and death.
Conclusion: Together, our findings suggest the shared genetics and causal association between AD and plasma ACE2 levels, which may partially explain the link between AD and COVID-19.

Keywords: ACE2; Alzheimer's disease; COVID‐19; SARS‐CoV‐2; expression quantitative trait loci; gene expression; genome‐wide association study.

 
Back
Top Bottom